Natera, Inc. (NASDAQ:NTRA - Get Free Report) CEO Steven Leonard Chapman sold 4,523 shares of the company's stock in a transaction dated Tuesday, October 15th. The shares were sold at an average price of $130.40, for a total transaction of $589,799.20. Following the completion of the sale, the chief executive officer now directly owns 191,163 shares of the company's stock, valued at $24,927,655.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.
Steven Leonard Chapman also recently made the following trade(s):
- On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The shares were sold at an average price of $128.48, for a total transaction of $645,483.52.
- On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The shares were sold at an average price of $118.91, for a total transaction of $663,874.53.
- On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $419,712.68.
- On Monday, July 22nd, Steven Leonard Chapman sold 2,638 shares of Natera stock. The shares were sold at an average price of $105.16, for a total value of $277,412.08.
Natera Stock Performance
Urgent: This election is rigged
From Porter & Company | Ad
If you missed it, my emergency election broadcast is now available - but will be removed soon
Click here to watch it now.
Shares of Natera stock opened at $122.35 on Friday. The firm has a market capitalization of $15.02 billion, a P/E ratio of -39.21 and a beta of 1.53. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $133.54. The firm's 50 day moving average is $123.15 and its two-hundred day moving average is $110.16.
Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period last year, the business earned ($0.97) EPS. Natera's revenue for the quarter was up 58.1% compared to the same quarter last year. Research analysts forecast that Natera, Inc. will post -1.96 EPS for the current fiscal year.
Institutional Trading of Natera
Several institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its holdings in shares of Natera by 0.7% in the first quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company's stock valued at $1,010,152,000 after acquiring an additional 72,848 shares during the period. Farallon Capital Management LLC raised its holdings in shares of Natera by 13.6% in the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company's stock valued at $483,034,000 after buying an additional 532,874 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Natera by 6.6% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company's stock worth $259,634,000 after buying an additional 148,917 shares during the period. Duquesne Family Office LLC increased its position in Natera by 2.4% in the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company's stock valued at $213,860,000 after acquiring an additional 45,500 shares during the period. Finally, Driehaus Capital Management LLC raised its stake in Natera by 14.6% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,220,768 shares of the medical research company's stock valued at $132,197,000 after acquiring an additional 155,802 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of analysts recently issued reports on NTRA shares. Robert W. Baird raised their price objective on Natera from $117.00 to $120.00 and gave the stock an "outperform" rating in a research report on Friday, August 9th. UBS Group dropped their price target on shares of Natera from $160.00 to $145.00 and set a "buy" rating for the company in a research report on Friday, August 9th. The Goldman Sachs Group upped their price objective on shares of Natera from $125.00 to $140.00 and gave the stock a "buy" rating in a report on Wednesday. Canaccord Genuity Group lifted their target price on shares of Natera from $130.00 to $145.00 and gave the company a "buy" rating in a report on Tuesday, August 27th. Finally, Morgan Stanley boosted their target price on Natera from $125.00 to $132.00 and gave the company an "overweight" rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company's stock. According to MarketBeat.com, Natera has an average rating of "Moderate Buy" and a consensus target price of $124.44.
Check Out Our Latest Stock Analysis on Natera
About Natera
(
Get Free Report)
Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
